An Imaging Agent (Perflutren Lipid Microspheres) with Ultrasound for Imaging of Prostate Cancer

This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.

Additional locations may be listed on ClinicalTrials.gov for NCT05336786.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase III

Trial Typediagnostic

Lead OrganizationThomas Jefferson University Hospital

Principal InvestigatorFlemming Forsberg

• Primary ID21G.1212
• Secondary IDsNCI-2022-01765
• ClinicalTrials.gov IDNCT05336786